Scholarlink

Background <p>The potential of marine algae as a source of antibacterial chemicals has been very promising. Numerous bioactive compounds produced by these organisms can fight off harmful microorganisms. Two marine algae (Chlorophyta: <i>Ulva lactuca</i>, Rhodophyta: <i>Pterocladiella capillacea</i>) were screened for their antibacterial activity against distinct multidrug-resistant bacteria <i>Klebsiella pneumoniae</i>. This efficiency is ascribed to the bioactive substances found in these algae, which have the ability to stop the growth of this harmful bacteria. <i>Pterocladiella capillacea</i> is a viable target for the development of novel antibacterial medications since its chemicals function by interfering with bacterial processes.</p> Results <p>A mixture of (<i>U. lactuca + P. capillacea.</i> + Nitrofurantoin) increased the inhibition zone on <i>K. pneumoniae</i> by 100%. Our docking findings demonstrated that benzo[h]quinoline, 2, 4-dimethyl-, and 4, 4’-Bis [4-methyl-2-pyrimidylsulfamido] terephthalanilide have a high affinity (-10 and − 11 respectively) to dock with the cell wall proteins of <i>Klebsiella pneumoniae</i>. It can cause cell lysis and death by interfering with the integrity of bacterial cell walls. Furthermore, it may disrupt DNA replication and vital bacterial enzymes. The molecule 4, 4’-Bis [4-methyl-2-pyrimidylsulfamido] terephthalanilide is a member of the sulfonamide class, which is well-known for its broad-spectrum antibacterial properties. This compound’s capacity to prevent bacteria from synthesizing folic acid is the main source of its antibacterial action. Bacterial cell division and DNA synthesis depend on folic acid. The substance successfully stops bacterial growth and multiplication by blocking this pathway.</p> Conclusion <p>These two substances are interesting candidates for the development of novel antimicrobial drugs due to their efficacy against strains of bacteria that are resistant to antibiotics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synergetic effects of Ulva lactuca and Pterocladiella capillacea on the multidrug-resistant Klebsiella pneumoniae

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月26日

查看全文
  • Rania M. Mahmoud,
  • Gehad M. Khedr,
  • Reda M. Taha,
  • Asmaa A. Adawy

摘要

Background

The potential of marine algae as a source of antibacterial chemicals has been very promising. Numerous bioactive compounds produced by these organisms can fight off harmful microorganisms. Two marine algae (Chlorophyta: Ulva lactuca, Rhodophyta: Pterocladiella capillacea) were screened for their antibacterial activity against distinct multidrug-resistant bacteria Klebsiella pneumoniae. This efficiency is ascribed to the bioactive substances found in these algae, which have the ability to stop the growth of this harmful bacteria. Pterocladiella capillacea is a viable target for the development of novel antibacterial medications since its chemicals function by interfering with bacterial processes.

Results

A mixture of (U. lactuca + P. capillacea. + Nitrofurantoin) increased the inhibition zone on K. pneumoniae by 100%. Our docking findings demonstrated that benzo[h]quinoline, 2, 4-dimethyl-, and 4, 4’-Bis [4-methyl-2-pyrimidylsulfamido] terephthalanilide have a high affinity (-10 and − 11 respectively) to dock with the cell wall proteins of Klebsiella pneumoniae. It can cause cell lysis and death by interfering with the integrity of bacterial cell walls. Furthermore, it may disrupt DNA replication and vital bacterial enzymes. The molecule 4, 4’-Bis [4-methyl-2-pyrimidylsulfamido] terephthalanilide is a member of the sulfonamide class, which is well-known for its broad-spectrum antibacterial properties. This compound’s capacity to prevent bacteria from synthesizing folic acid is the main source of its antibacterial action. Bacterial cell division and DNA synthesis depend on folic acid. The substance successfully stops bacterial growth and multiplication by blocking this pathway.

Conclusion

These two substances are interesting candidates for the development of novel antimicrobial drugs due to their efficacy against strains of bacteria that are resistant to antibiotics.